

Behçet's syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/BB33402615C1EN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: BB33402615C1EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Behçet's syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Behçet's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Behçet's syndrome Understanding

Behçet's syndrome: Overview

Behçet's syndrome is a rare multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. Symptoms include mucous membrane lesions of the mouth (canker sores) and genitals (ulcers) that tend to disappear and recur spontaneously. Inflammation of the eyes (anterior uveitis, posterior uveitis, or panuveitis) also affects individuals with Behçet's syndrome. Additional systems of the body may also be affected including the joints, blood vessels, central nervous system, and/or digestive tract. The exact cause of Behçet's syndrome is unknown.

'Behçet's syndrome - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Behçet's syndrome pipeline landscape is provided which includes the disease overview and Behçet's syndrome treatment guidelines. The assessment part of the report embraces, in depth Behçet's syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Behçet's syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Behçet's syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Behçet's syndrome.

Behçet's syndrome Emerging Drugs Chapters

This segment of the Behçet's syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Behçet's syndrome Emerging Drugs

Hemay005: Tianjin Hemay Pharmaceutical

Hemay005 is an orally available Type 4 cyclic nucleotide phosphodiesterase inhibitor. . The company is conducting Phase II study to evaluate the efficacy and safety of Hemay005 in the treatment of Behçet Disease.

Canakinumab: Novartis

Canakinumab is a human monoclonal IgG1 that selectively neutralizes IL-1 β , inhibiting its binding to IL-1RI and all cytokine-dependent signaling pathways. This results in the

suppression of inflammation in patients with disorders of autoimmune origin.

Further product details are provided in the report.

Behçet's syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Behçet's syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Behçet's syndrome

There are approx. 3+ key companies which are developing the therapies for Behçet's syndrome. The companies which have their Behçet's syndrome drug candidates in the most advanced stage, i.e. phase II include, Tianjin Hemay Pharmaceutical.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Behçet's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Beh?et's syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beh?et's syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beh?et's syndrome drugs.

Beh?et's syndrome Report Insights

Beh?et's syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Beh?et's syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Beh?et's syndrome drugs?

How many Beh?et's syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beh?et's syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Behçet's syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Behçet's syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tianjin Hemay Pharmaceutical

Actelion Pharmaceuticals

Novartis

Silk Road Therapies, Inc.

Key Products

Hemay005

Bosentan

Canakinumab

Contents

Introduction

Executive Summary

Beh?et's syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Beh?et's syndrome – DelveInsight's Analytical Perspectives

Mid Stage Products (Phase II)

Comparative Analysis

Hemay005: Tianjin Hemay Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Inactive Products

Comparative Analysis

Beh?et's syndrome Key Companies

Beh?et's syndrome Key Products

Beh?et's syndrome- Unmet Needs

Beh?et's syndrome- Market Drivers and Barriers
Beh?et's syndrome- Future Perspectives and Conclusion
Beh?et's syndrome Analyst Views
Beh?et's syndrome Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Behçet's syndrome
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Behçet's syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Beh?et's syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/BB33402615C1EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BB33402615C1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970